The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519976-19-00

Acronym

223529

Enrollment

Registered

2025-10-20

Start date

2025-11-26

Completion date

Unknown

Last updated

2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma with type 2 inflammation characterized by an eosinophilic phenotype

Brief summary

Change from baseline in total mucus plug volume measured at TLC at Week 26

Detailed description

Change from baseline in airway wall thickness measured at TLC at Week 52.

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in total mucus plug volume measured at TLC at Week 26	—

Secondary

Measure	Time frame
Change from baseline in airway wall thickness measured at TLC at Week 52.	—

Countries

Belgium, France, Germany, Greece, Italy, Spain

Outcome results